gros paiement d'étape le 01 mars donc compris dans le t1 2011+ news conference
|Cercle Finance le 01/03/2011 à 10:10
Innate Pharma : a reçu un paiement d'étape pour l'IPH 2201.
(CercleFinance.com) - Innate Pharma a annoncé hier soir qu'une demande d'essai clinique en Europe
a été déposée par Novo Nordisk A/S pour IPH 2201 (NN8765), ce qui a déclenché un paiement
d'étape ' significatif ' pour Innate Pharma.
Dans son communiqué, la société biopharmaceutique rappelle qu'IPH 2201 est un anticorps
humanisé, issu de sa collaboration avec Novo Nordisk A/S, et développé dans l'inflammation et
les maladies auto-immunes.
' IPH 2201 pourrait être le troisième anticorps monoclonal issu de notre collaboration avec Novo
Nordisk A/S à entrer en essai clinique, après IPH 2101 et NN8555 ', a déclaré Hervé Brailly,
le Président du Directo ire d'Innate Pharma.
IPH 2201 devrait en effet entrer en essai clinique de Phase I en 2011. Innate Pharma est éligible
à des paiements d'étape pour le développement de IPH 2201 et à des royalties sur les ventes
futures.
+
A PHASE I TRIAL OF IPH-2101, A NOVEL ANTI-INHIBITORY KIR ANTIBODY, IN PATIENTS WITH MULTIPLE MYELOMA
D. BENSON(1), C. BAKAN(1), C. HOFMEISTER(1), Y. EFEBERA(1), A. SUVANNASANKHA(2), S. JAGGANATH(3), R.
ABONOUR(2), A. CHARI(3), S. PADMANABAN(4), F. ROMAGNE(5), P. ANDRE(5), S. BLANCHET(5), R. BUFFET(5),
M. CALIGIURI(1), S. FARAG(2)
(1) The Ohio State University, COLUMBUS, UNITED STATES ; (2) Indiana University Cancer Center,
INDIANAPOLIS, UNITED STATES ; (3) Mt Sinai Cancer Center, NEW YORK, UNITED STATES ; (4) Cancer
Treatment and Research Center, SAN ANTONIO, UNITED STATES ; (5) Innate Pharma, MARSEILLE, FRANCE
Background: Multiple myeloma (MM) cells upregulate MHC class I as ligands to inhibitory killer
immunoglobulin-like receptors (KIR) on natural killer (NK) cells. IPH-2101, an anti-KIR antibody,
enhances NK cell function against cancer by disrupting inhibitory KIR/ligand relationship. Methods:
A dose-escalation study was conducted in previously treated patients (pts) with MM in 7 cohorts
(0.0003 to 3mg/kg IV q28-d for up to 4 cycles) in a 3+3 design (with a 7-pt extension at 3mg/kg in
pts with one prior therapy). Pharmacokinetic (PK), pharmacodynamic (PD), safety and biologic data
were collected. Results: 32 pts (med age = 61, prior therapies = 1-7) were treated. Full KIR
saturation over dosing interval was achieved without DLT. The median number of IPH-2101 doses
received was 2, 31% of pts received all 4 doses. 12% of AEs were reported (mild or moderate)
“possibly” or “probably” related to IPH-2101. 1 SAE occurred (acute renal failure). PK and
PD data closely approximated preclinical models, IPH-2101 had no effect on NK cell maturation but
enhanced ex vivo NK cell cytotoxicity against MM. 12 pts had stable disease. Conclusions: IPH-2101
is safe and tolerable with doses that achieve full KIR saturation over the dosing interval. Cmax and
KIR occupancy correlate, and IPH-2101 enhances NK cell cytotoxicity against MM. 38% of pts achieved
a best response of stable disease. Phase II studies in maintenance after autologous SCT and in
smoldering MM as well as a phase I/II trial of IPH-2101 and lenalidomide are underway. Final results
will be presented.
